Use of Vacuum-assisted closure in management of open abdominal wound with multiple enterocutaneous fistulae during chemotherapy: A case report  by Fujino, Shiki et al.
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INTRODUCTION:  Vacuum-assisted  closure  (VAC)  is useful  for treating complex  wounds  because  it pro-
motes granulation.  In the  present  report,  a  successful  case  of  VAC  used  for an  open  abdominal  wound
with  enterocutaneous  ﬁstulae  after  multiple  intestinal  perforations  during  chemotherapy  is described.
PRESENTATION  OF CASE:  A  73-year-old  man  was admitted  to our  hospital  with  severe  abdominal  pain.  He
underwent  surgical  resection  for ascending  colon  cancer  4  years  ago  and  was  administered  chemotherapy
with  bevacizumab  for recurrence.  Physical  examination  and computed  tomography  revealed  perforation
of the intestine,  and  an  emergency  operation  was  performed.  Following  this  procedure,  other  intestinal
perforations  occurred,  resulting  in an  open  abdominal  wound  at postoperative  day  (POD)  10. To isolate
enteric  contents  and  promote  granulation,  VAC  was  applied  to  the  abdominal  wound  with  enterocuta-
neous  ﬁstulae.  Oral  intake  started  at POD 21  and  the wound  size  became  smaller.  Further,  an ostomy
bag  was  directly  attached  to the most  oral  perforation  site.  The  patient  recovered  from  life-threatening
events  without  severe  infection  and  was  transferred  to  another  hospital  close  to his home  at  POD  180.
DISCUSSION:  Gastrointestinal  perforation  is  known  to be  one  of the fatal  adverse  events  of  bevacizumab.
In  this  case  four  gastrointestinal  perforations  were  observed.  Isolation  of  enteric  contents  is important
to  heal  the  wound  and VAC  is  an  effective  therapy  for the  management  of  open  abdominal  wounds  even
with  enterocutaneous  ﬁstulae.
CONCLUSION:  Innovative  VAC  use for the  management  of open  abdominal  wounds  can  improve  the
nutritional  status  and  overall  wound  healing  of the  patient.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Vacuum-assisted closure (VAC) was ﬁrst reported in 1997 [1,2].
t aids in secondary wound healing and has become the most com-
on  treatment modality for complex wounds. An open-cell foam
ressing placed into the wound cavity and applying controlled neg-
tive pressure decrease bacterial colonization, tissue edema, and
ound tension and increase blood ﬂow. Using these strategies, VAC
romotes wound granulation [2,3]. VAC has been recently used
Abbreviations: VAC, vacuum-asssisted closure.
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in gastrointestinal surgery ﬁeld and for open abdominal wounds
[4–6]. It can shorten time for reconstruction. However there are a
few reports regarding the use of VAC for open abdominal wounds
with enterocutaneous ﬁstula [7,8]. Exposure to enteric contents
results in wound inﬂammation and infection, with the further effect
of protracted wound healing. Therefore the drainage system is the
most critical management factor in wounds with enterocutaneous
ﬁstula. In addition the patient was treated with bevacizumab which
is reported to increase wound healing complications. Herein we
report the successful case to be treated by VAC for an open abdom-
inal wound with enterocutaneous ﬁstulae, and the present report
is the ﬁrst successful case of multiple gastrointestinal perforations.
1.1. Presentation of caseA 73-year-old man  was  admitted to our hospital with severe
abdominal pain in March 2014. He had a medical history of sur-
gical resection for ascending colon cancer at another hospital in
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Aig. 1. Abdominal computed tomography (CT) images of an intestinal perforation.
T image revealed free air (arrows) in the upper space of the abdomen (A) and also
une 2010. The right iliopsoas muscle and right femoral nerve were
artially resected as part of the cancer treatment. The ﬁnal stage
as IIIb (T4bN1bM0) according to the UICC TNM classiﬁcation [9],
nd the cancer microscopically remained at the surgical excision
ite around the right external iliac artery. Therefore, 5-ﬂuorouracil-
ased chemotherapy, UFT (300 mg/m2/day × 28 days/5 weeks) and
adiotherapy (50 Gy to the right external iliac artery) were post-
peratively administered. In October 2012, there was a clear
ecurrence of the cancer at the surgical site, and the patient
as admitted to the Department of Clinical Oncology at Osaka
edical Center for Cancer and Cardiovascular Diseases. Due to
ecurrence, several chemotherapies (CapeOX, mFOLFOX6, FOLFIRI)
ith bevacizumab had been administered according to the guide-
ines provided by the Japanese Society for Cancer of the Colon and
ectum [10] in the outpatient clinic.
Abdominal computed tomography (CT) revealed perforation of
he intestine (Fig. 1), and an emergency operation was performed.
t surgery, perforation of the sigmoid colon was  detected; it was
utured and a diverting ileostomy was performed. On POD 8, a new
erforation of the small intestine occurred and a second emergency
peration was  performed. At that time, there were severe adhesions
f the small intestine; therefore a suture or resection of the intes-
ine with the perforation could not be performed. To isolate the
nteric contents, a drainage tube was positioned in the perfora-
ion site, and the abdominal wall was sutured. However, drainage
f enteric contents through the drainage tube was  not effective,
nd the abdominal wound reopened 2 days later (POD 10 after
he ﬁrst operation) (Fig. 2). In general, enteric contents prevent
he wound healing, and it was difﬁcult to manage the drainage at
his time. Therefore we introduced VAC therapy (VAC; KCI Inter-
ig. 2. Photograph of the open abdominal wound with intestinal perforation at POD 10.
 drainage tube (arrow) was placed into the small intestine through a perforation site in  lower space of the abdomen (B).
national, San Antonio, TX, USA) to minimize abdominal wound
infection by isolating enteric contents as well as to promote wound
granulation. VAC therapy was  administered using a VAC system.
The entire wound surrounding the ﬁstulae was treated with VAC
therapy (Fig. 3). First, the open wound was  washed by saline and
an atraumatic contact layer, either Mepitel One (Mölnlycke Health
Care, Norcross, GA, USA) and GranuFoam (KCI international), was
cut to the shape of the abdominal wound, excluding the ﬁstula
holes. The intestinal wall, except the perforation sites, was  cov-
ered with the atraumatic contact layer as bleeding or perforation of
the intestine can occur when the intestine directly contacts Granu-
Foam [11,12]. Next, GranuFoam was positioned on the atraumatic
contact layer. These layers were then covered with a polyurethane
drape (VAC drape), and continuous negative pressure was applied
(75 mm Hg). Enteric contents were suctioned using a Continuous
Suction Unit MERA Sucuum (Senko Medical Instrument Manu-
facturing CO, Tokyo, Japan) set to 50 mm Hg continuous negative
pressure. Although two additional perforations of the small intes-
tine were observed on POD 11 and POD 14, the additional enteric
contents were effectively isolated by the VAC system, and it was
continued. An ostomy bag was attached to the VAC drape at the
most oral perforation site of the intestine, and oral intake started
on POD 21 (Fig. 4). The VAC system was considered effective in pro-
moting the granulation tissue covering both the intestinal wall and
wound bed. Three months after the administration of VAC, enteric
contents could be separated into an ostomy bag without suction
using MERA Sucuum at the most oral perforation site.Although the wound granulated well over the exposed intestine,
the VAC system was still required to anchor the ostomy bag for
drainage of enteric contents. In order to directly attach an ostomy
the second emergency operation.
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Fig. 3. Photographs of VAC therapy for open abdominal wound with ﬁstulae.
(A)  Open abdominal wound at POD 11. An arrow shows the most oral perforation site, which is the same site showed in Fig. 2. Arrowheads show other perforations. (B)
Mepitel  one was  cut to the shape of the open abdominal wound and a hole was  created for the drainage of enteric contents. (C) GranuFoam was also cut to the shape of the
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ipen  abdominal wound with a hole for drainage of enteric contents. (D) The wound
egative  pressure was then applied and another suction tube (arrowhead) was pos
f  50 mmHg.
ag, an operation was performed to cover the granulation tissue
ith skin. A portion of the skin around the most oral perforation
ite was then cut and rotated to cover the granulation tissue at POD
02, and the wound contracted (Fig. 5). Change and replacement of
AC was necessary approximately once a week. At POD 180, the
otated skin around the most oral perforation site healed well and
ppeared to be “a uniforate stoma,” allowing an ostomy bag to be
irectly attached without the VAC system. The patient was  then
ransferred to another hospital close to his home.
. DiscussionA humanized anti-vascular endothelial growth factor mono-
lonal antibody, bevacizumab, has been reported to be useful
or several cancer therapies and also for colorectal cancer ther-
ig. 4. Photographs of the open abdominal wound on POD 21.
A) The wound was  almost covered with healthy granulation tissue. (B) The ostomy bag 
n  Fig. 3D, and suction pressure of 50 mmHg  was  continued to drain intestinal contents.overed with a ﬁlm and a VAC connecting tube (arrow) was  afﬁxed to it. Controlled
d at the most oral perforation site for the suction of enteric contents at a pressure
apy [10,13]. However, gastrointestinal perforation was observed
in 0.9% of patients who  underwent chemotherapy with beva-
cizumab for colorectal cancer, and bevacizumab was  reported to
increase wound healing complications [14,15]. High dose of beva-
cizumab (5.0 mg/kg/week) or concurrent use with chemotherapy,
such as oxaliplatine, was reported to increase gastrointestinal per-
foration [14]. In the present case, oxaliplatine was used as part
of chemotherapy, and 5.0 mg/kg/week bevacizumab was  adminis-
tered when the perforation occurred. Gastrointestinal perforation
is one of the fatal adverse events of bevacizumab [16–18]. The
mortality of gastrointestinal perforation was  21.7% in cancer
patients treated with bevacizumab, whereas it was 15.7% with-
out bevacizumab [19]. The mechanism of bowel perforation with
bevacizumab is poorly understood, but it increases the risk of
arterial thromboembolic events and venous thromboembolism
was  attached to the most oral perforation site instead of the suction tube depicted
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Fig. 5. Scheme of the skin rotation and photographs of the open abdominal wound on POD 102 and POD 174.
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ﬁA)  The dark gray closed circle indicates the most oral perforation site and white g
ine,  and two skin ﬂaps (star and rhomboid) were created. The left side skin was  cut 
issue.  (C) Healthy granulation tissue was observed on POD 102 prior to skin rotatio
20,21]. It suggests that bevacizumab damages gastrointestinal ves-
els, resulting in ischemic perforation of the normal bowel wall.
herefore, an appropriate treatment is necessary on the case. In
his case all perforations occurred within 6 weeks following the
nal administration of bevacizumab; to the best of our knowledge,
his is the ﬁrst report of multiple intestinal perforations related
o bevacizumab. Gastrointestinal perforations and open abdomen
ere life-threatening events; therefore, we controlled the infection
nd promoted secondary wound healing with VAC.
In a case of open abdomens with enterocutaneous ﬁstulae,
xtensive wound care such as negative pressure wound therapy
s effective, and mortality rates and recovery can be improved by
utritional support [22]. Therefore isolating enteric contents is the
ost important factor in the prevention of infection and promo-
ion of wound healing. A few studies reported the usefulness of
AC for open abdomens with enterocutaneous ﬁstula, and VAC has
ot been reported to confer any additional morbidity or risk of new
stula formation [7,8,23]. It was reported that VAC therapy with sil-
cone ﬁstula plug and platelet gel, and low intestinal pressure are
ffective to manage the ﬁstula [24–26]. In the present case, there
ere multiple ﬁstulae and we made “a uniforate stoma” at the most
ral ﬁstula by suction using MERA Sucuum. Enteric contents were
lmost entirely isolated, leading to early oral intake for nutritional
ecovery.
The patient recovered from life-threatening gastrointestinal
erforations and open abdomen, which are difﬁcult to manage. VAC
nd isolation of enteric contents using MERA Sucuum enabled to
revent infection and early oral intake. Therefore, VAC was one
f the useful treatments of open abdomen with enterocutaneous
stulae.osed circles indicate the other perforation sites. The skin was cut along the dotted
tated (3). (B) Two  skin ﬂaps (star and rhomboid) were rotated onto the granulation
 The skin ﬂap adhered to the healthy granulation tissue on POD102.
3. Conclusions
VAC is an effective therapy for the management of an open
abdominal wound with enterocutaneous ﬁstulae during the treat-
ment of bevacizumab and improves the nutritional status of the
patient in addition to providing appropriate wound treatment.
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